key: cord-0757274-rso45gkx
authors: Rees, E. M.; Nightingale, E. S.; Jafari, Y.; Waterlow, N.; Clifford, S.; CMMID Working Group,; Jombert, T.; Procter, S. R.; Knight, G. M.
title: COVID-19 length of hospital stay: a systematic review and data synthesis
date: 2020-05-05
journal: nan
DOI: 10.1101/2020.04.30.20084780
sha: 48a0aadb24f38bfbc7fccd4e48a3f84c9459fa3f
doc_id: 757274
cord_uid: rso45gkx

Background The COVID-19 pandemic has placed an unprecedented strain on health systems, with rapidly increasing demand for healthcare in hospitals and intensive care units (ICUs) worldwide. As the pandemic escalates, determining the resulting needs for healthcare resources (beds, staff, equipment) has become a key priority for many countries. Projecting future demand requires estimates of how long patients with COVID-19 need different levels of hospital care. Methods We performed a systematic review to gather data on length of stay (LoS) of patients with COVID-19 in hospital and in ICU. We subsequently developed a method to generate LoS distributions which combines summary statistics reported in multiple studies, accounting for differences in sample sizes. Applying this approach we provide distributions for general hospital and ICU LoS from studies in China and elsewhere, for use by the community. Results We identified 52 studies, the majority from China (46/52). Median hospital LoS ranged from 4 to 53 days within China, and 4 to 21 days outside of China, across 45 studies. ICU LoS was reported by eight studies - four each within and outside China - with median values ranging from 6 to 12 and 4 to 19 days, respectively. Our summary distributions have a median hospital LoS of 14 (IQR: 10-19) days for China, compared with 5 (IQR: 3-9) days outside of China. For ICU, the summary distributions are more similar (median (IQR) of 8 (5-13) days for China and 7 (4-11) days outside of China). There was a visible difference by discharge status, with patients who were discharged alive having longer LoS than those who died during their admission, but no trend associated with study date. Conclusion Patients with COVID-19 in China appeared to remain in hospital for longer than elsewhere. This may be explained by differences in criteria for admission and discharge between countries, and different timing within the pandemic. In the absence of local data, the combined summary LoS distributions provided here can be used to model bed demands for contingency planning and then updated, with the novel method presented here, as more studies with aggregated statistics emerge outside China.

As of the April 28th 2020, there have been over 3 million confirmed cases of COVID-19 and more than 200,000 deaths across 185 countries and territories [1] . Health systems are challenged by the influx of patients as SARS-CoV-2, the pathogen causing COVID-19, has spread throughout the world since its emergence in late . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2020. . https://doi.org/10.1101/2020.04. 30.20084780 doi: medRxiv preprint December 2019 [2] [3] [4] [5] [6] . The risks of healthcare services being overwhelmed was most dramatically illustrated in Italy, where a rapid increase of COVID-19 cases needing hospitalisation pushed a well-equipped health system of 3.2 hospital beds per 1,000 people to breaking point [7] . This raises serious concerns over the potential impact on more resource-constrained health systems in low-and middle-income countries (LMICs) as epidemics begin to expand across Africa and South America.

Understanding and predicting hospital bed demand (as well as associated staff or equipment requirements) provides crucial evidence for decision-making and contingency planning (7, 8) . Predicting demand for hospital services requires an estimate of the number of patients requiring hospitalisation, and an estimate of how long each person will require hospital care. It is possible to model the rate of hospitalisation in many settings based on estimated epidemic curves. However, estimating length of stay (LoS) in hospitals requires observation of individual patient pathways.

COVID-19 presents at varying levels of severity. Hospital care can vary from general ward based care to high dependency units with oxygen support to intensive care where patients may be intubated for mechanical ventilation [8] [9] [10] . The LoS is likely to depend on the level of care required, as well as the geographic setting due to varying COVID-19 care guidelines. For example, some hospitals in China were initially used as isolation settings [11, 12] . As knowledge of effective treatments changes, the pathways, staff, beds and equipment required are also likely to affect the duration and level of care needed. Moreover, patient characteristics -such as age and comorbidities -impact disease severity [8, [12] [13] [14] and are likely to influence LoS. If differences are significant then capacity planning may need to account for these characteristics to provide accurate predictions of the number of beds required at each level of care. Modelling studies predicting bed occupancy published so far have broadly relied on very few sources of information for LoS estimates, which were often derived from very different settings [15] [16] [17] [18] [19] [20] [21] [22] . Estimates for LoS can be obtained from a variety of studies, but are often an incidental result rather than a study's primary outcome, and typically only summary statistics are reported. In general, LoS distributions are right-skewed due to a minority of patients with long hospital stays and are often modelled using gamma, log-normal or weibull distributions [23] (although log-normal is less preferred due to its heavier tails). A particular challenge is how to synthesise appropriate LoS distributions from a range of relevant sources in similar settings, capturing the variation both within and between them. Incorporating the uncertainty and stochasticity in parameters using a distribution, rather than fixed point estimates (such as the mean over all studies), allows for more realistic model predictions.

We performed a systematic review to identify the current evidence on LoS for COVID-19 patients worldwide. We also present a method for generating LoS summary distributions by combining information from different summary statistics (mean and medians) reported in multiple studies, and accounting for differences in sample sizes. In doing this work, we aim to inform the efforts of modellers and policy makers to better anticipate healthcare needs during the evolving COVID-19 pandemic.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2020. . https://doi.org/10.1101/2020.04. 30.20084780 doi: medRxiv preprint 1 Studies were excluded if LoS was reported for individuals only admitted to hospital for a reason other than confirmed or suspected COVID-19 2 Studies where the LoS endpoint was not death or discharge or continuing stay, for example transfer to another hospital 3 Studies which stated that hospitalisation was used as a form of isolation 4 Studies not published in English 5 Review articles

The screening process is summarised in Fig. 1 . All titles and abstracts were screened independently by two reviewers (EMR and SRP). Subsequently, abstracts and full texts of potentially relevant papers were independently reviewed by two reviewers (EMR and YJ). CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 5, 2020. 

The data that was extracted from each study is presented in Supplementary Table  A . Data extraction was performed by EMR, YJ and ESN, and then verified by a second member of the study team. Study characteristics (such as study dates, study population and study design) were recorded from each study, as well as information on the LoS sample estimate for both general hospital and intensive care units (ICUs), including sample size, discharge status and completeness of followup. If multiple LoS estimates were reported for different study populations these were all recorded (for example, LoS reported by disease severity, comorbidities and treatment groups). One study specified non-ICU LoS and this was grouped with general LoS estimates; ICU LoS was reported separately. Average patient age and sex distribution (% male) were summarised across all studies by weighted mean and standard deviation (mean (sd)), according to study sample size.

Where possible, LoS estimates were recorded as median and IQR. Otherwise, mean and SD, or in some cases only a point estimate was provided. Where estimates were presented as a mean, x, and standard deviation, s, we calculated the comparable quantiles from a fitted Weibull distribution by moment-matching using the mixdist package [24] and then discretising using the distcrete package [25] in R .

Overall summary distributions were created for general hospitalisation LoS and for ICU LoS. We included studies in the estimation of these summary distributions if they reported both the sample size along with either the median and interquartile range or the mean and standard deviation. If no measure of variation was provided (either IQR or standard deviation), the point estimates were included in figures but excluded from these summary results.

A Weibull distribution was fitted to the summary data from each grouping (by country setting and general/ICU classification) in the appropriate studies, using the Nelder-Mead method (using the stats package in R [26] )for those reporting medians and IQRs, and the mixdist package [24] for those reporting means and standard deviations (as described in the previous section). The same approach was also tested using gamma distributions, but Weibull was marginally preferred with respect to total squared error in the fitted quantiles. These distributions were then discretised using the distcrete package in R [25] . 100,000 samples were then drawn from each of these distributions, with weighting according to their sample size. Specifically, the study distributions were first sampled according to a multinomial distribution defined by the studies' relative sample sizes, and LoS was then sampled from each of these sampled distributions. Due to potential important differences in the characteristics of each study population, it may not be appropriate to weight entirely on sample size without considering how representative the cohort is of the general population. Therefore, as a sensitivity analysis, we performed the same analysis without weighting in order to understand how much this influences the distribution.

All analyses were performed using R version 3.6.3 (2020-02-29).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 5, 2020. . https://doi.org/10.1101/2020.04. 30.20084780 doi: medRxiv preprint

The results of our screening process are summarised in Fig. 1 . After removing duplicates we found a total of 650 potentially eligible studies of which 52 studies met all the inclusion criteria. These included 32 peer-reviewed articles from the academic literature, 18 pre-print articles, and 2 reports from other sources ( [27] and [28] ). Several studies reported LoS by specific patient subgroups, according to disease severity, comorbidities (kidney injury, liver injury, hypertension, and cardiac injury), experimental treatments (heparin, lopinavir-ritonavir) and pregnancy status. A complete description of all reported LoS estimates are provided in Supplementary  Table B . The key characteristics of the included studies are summarised in Table 1 .

The studies were carried out between 2019-12-24 and 2020-04-16. Although the cut-off was 2020-04-12 for inclusion of published and pre-print studies, the most recent version of the ICNARC report [28] was used, which included patients admitted up to 2020-04-16. The majority of studies were cohort studies (46/52), with four cross-sectional studies, one case-control and one randomised control trial (RCT). Two articles were reports from on-going data-collections (ISARIC [27] , 2020-04-08, and ICNARC [28], 2020-04-16).

Studies were mostly conducted in adults with average participant age from 19 to 76 years (mean (sd) across studies, weighted by sample size: 59 (9.6) years), and overall reported only a slightly higher proportion of males to females (54 (10.9) % male). Three pediatric studies included patients from newborn to 18 years, with a weighted mean (sd) of 7 (2.8) years of age [29] [30] [31] . For the majority of studies LoS was a secondary or incidental outcome rather than the primary outcome. As a result, age and sex distributions were not always specific to the LoS population, and instead reported for the overall study population. Furthermore, it was not always possible to accurately interpret the sample size of the population, nor whether the LoS estimate included still-hospitalised patients. All LoS data extracted from studies are reported in Supplementary Table B .

The majority of the included studies (46/52) were based in China, with a particularly high number reported from Wuhan (27/46) , and many study populations were from the same Outside of China, there was one study from Italy [32] , one for the whole EU region [33] , two from the United States [34, 35] , one from the United Kingdom [28] and one study that collated LoS estimates from multiple countries excluding China (although the majority of the data are from the UK; [27] ).

Most studies (43/52) reported LoS for general hospitalisation only, with four studies reporting LoS for ICU only, and five studies reporting both. Only 15 studies reported LoS for study populations with completed follow-up (patient discharge or death), with 37 reporting estimates for populations where some patients remained in hospital or in ICU. The majority of studies only included discharged or dead patients within their LoS estimate, even if they had incomplete follow-up of the full cohort. However, for 8 studies it was unclear whether the reported LoS included patients who were still hospitalised [33, 34, [36] [37] [38] [39] [40] [41] .

Overall hospital length of stay Estimates of the overall hospital LoS are summarised in Fig. 2 . Where provided, the overall study estimate of LoS for each discharge status is presented. For three . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 5, 2020. . https://doi.org/10.1101/2020.04. 30.20084780 doi: medRxiv preprint studies, LoS was only reported within specific patient subgroups (relating to cardiac injury [42] , COVID-19 recovery trajectory [43] and treatment comparison arms [44] ), therefore in these cases we include both estimates. The longest stays were recorded in a study of five critically ill patients [45] , of whom only three were discharged and all more than 50 days after admission, which does not appear representative of the overall distribution (see Fig. 2 , Shen et al. (2020-01-20) ). Excluding this study, the median duration of hospitalisation ranged from 5 to 29 days. There was no observed trend with respect to when the study was conducted (Fig 2) .

Estimates for LoS amongst patients who died in hospital were generally shorter than those for patients who were discharged alive, with medians between 4 and 21 days compared to 4 and 53 days, respectively. This difference is apparent in Fig. 2 , where median LoS was lower for those discharged alive in 6 out of 8 studies that reported both outcomes. In studies that reported general hospital LoS by disease severity (11 studies, Supplementary Fig. A) , there was a trend towards more severe cases having longer LoS. However, the definition of different levels of severity was inconsistent between studies so it is not possible to draw any confident conclusion.

Visual inspection of the study estimates suggested some evidence of a difference between general hospital LoS reported within and outside China, but studies outside China were too few (5/48) for a formal comparison. However, LoS reported within the ISARIC report [27] in particular (which includes contributed data from 25 countries, but with the majority of patients from the UK) gave a median and IQR (4 days (1 -9)) substantially lower than the weighted mean from the studies from China (15.3 days).

The patient populations observed in these studies covered a wide range of ages, including three pediatric studies [29] [30] [31] . Among patients discharged alive there appears to be little difference in average LoS between studies with the youngest and oldest patients, but the longest estimates came from studies with average age in the upper end of the range (Wang et al. [39] and Shi et al. [44] , with average age of 68 and 69, respectively; Supplementary Fig. B ). The LoS estimates which included non-survivors tended to come from studies with older populations, as is to be expected given the well-documented, age-dependent fatality rate [46] .

Median stay in ICU ranged from 5 (IQR 2 -9) to 19 (No IQR reported) days. There appeared to be less of a difference according to discharge status (alive or dead) than there was for general LoS (Fig. 3) . A total of 8 studies reported ICU LoS estimates, with the same number of studies reporting LoS estimates from China and outside of China, and the resulting overall estimates are very similar. There were too few studies to conduct any comparison by age or disease severity. Fig. 4 . The median and IQR for general hospital was estimated to be 14 (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) for China and 5 (3-9) excluding China. This was also repeated for ICU LoS, with a median and IQR 8 (5-13) for China and 7 (4-11)

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2020. . https://doi.org/10.1101/2020.04. 30.20084780 doi: medRxiv preprint outside China. Studies from China which had complete follow-up with respect to general hospital LoS were compared with studies with incomplete follow-up. A slight difference was observed, with shorter median LoS observed in studies with complete follow-up (median, 12; IQR 8 -17) compared with incomplete follow-up (median, 14; IQR, 10-19; Supplementary Fig. C) . This was only performed for general hospital LoS in China, since no studies from outside China reported completed LoS for ICU.

For general hospital LoS in China, five studies were not included since they only provided point estimates for the LoS. The point estimates from four of these studies fell within the IQR of the estimated distribution, however, for [45] , the point estimate was much longer. For general LoS outside of China, one study reported only a point estimate [33] , and this also fell outside of the estimated IQR. Sensitivity analysis showed that weighting by sample size had minimal influence on the shape of these distributions ( Supplementary Fig. D) . 

Understanding how long patients hospitalised with COVID-19 remain in hospital is critical for planning and predicting bed occupancy as well as associated staff and equipment needs. This review found that hospital LoS observations for COVID-19 patients published in the literature to date varied from less than a week to nearly two months. Stay in intensive care was shorter and less variable, with studies reporting medians of one to three weeks. Where LoS was reported according to discharge status, stay was found to be shorter for those who died than for those discharged alive; however, this difference was only apparent in terms of overall stay and not stay in ICU (no statistical comparison was made). With respect to practical implications, knowledge of a difference between survivors and non-survivors is of less use since the outcome will not be known in advance in order to influence decision-making.

To the authors' knowledge, this is the first formal review that has been conducted on hospital LoS for COVID-19. The included studies yield some evidence of a difference between total hospital LoS observed in China and outside of China, with shorter LoS reported in the latter group (14 days (10-19) versus 5 days (3-9), respectively). However, only five studies were identified which reported LoS outside of China therefore this comparison is somewhat inconclusive. It may be that LoS is longer in China compared with other settings due to different criteria for hospital admission and discharge. A consensus exists across guidelines, such as ensuring resolution of symptoms and evidence of two negative PCR samples at least 24 hours apart before discharge [47, 48] , however, differences between settings may arise as a result of local capacity and strain on the health system. We attempted to capture this difference by recording time from onset of symptoms to admission, however, only one study outside of China reported this and a comparison was not possible. It is also possible that, with foresight from witnessing the Chinese epidemic, other countries set less strict criteria for discharge, in anticipation of stretched capacity. Other countries may also have used evidence from China to improve treatment methods and hence shorten LoS. However, this unfortunately appears unlikely as we did not observe a trend when looking at the reported LoS estimates over time.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2020. . https://doi.org/10.1101/2020.04. 30.20084780 doi: medRxiv preprint In contrast, no difference was observed between settings for ICU LoS, for which there were an equal number of studies included from within and outside China. It is important to note that there might be key differences between ICUs in China compared with other countries, yet a definition for what constituted an ICU was rarely reported. Previous studies have found that ICU characteristics varied widely across geographic regions [49] . Further understanding of characteristics of ICUs reporting LoS for patients with COVID-19 are important in providing context on the reported estimates and should be investigated in future studies.

There appeared to be little difference of LoS observed by age in our results, apart from the fact that studies which reported deaths tended to have older patient populations. However, if there is indeed a trend we were unlikely to observe strong evidence for it amongst these studies, since the majority include a similar mix of ages, often tending towards older cohorts, and the age distribution was not always provided for the specific subgroup who had LoS recorded. Two studies [27, 38] were included in the review which reported LoS by age, and they both found longer LoS associated with older age groups. In addition, a study of LoS from the USA which was published after the search dates also reported a trend for longer LoS in older age groups [50] .

Having been the first country to observe this novel coronavirus, published data on COVID-19 patient outcomes in China is more widely available than from countries to which the epidemic spread later on. The set of studies found in this review reflects this bias towards evidence obtained from China, particularly Wuhan. As more studies emerge from a broader range of settings it would be important to re-evaluate LoS estimates, as there are likely to be between-country differences that we have not captured here.

Furthermore, a number of studies include patients from the same hospital over the same period, for example, Yang et al. [51] and Wu et al. [52] who both reported patients from Jin Yin Tan hospital in Wuhan), and it is possible that these studies had overlapping study populations. Furthermore, Guan et al. [36] was a national study conducted in China and ISARIC [27] included 25 countries world-wide, therefore these studies may also include patients previously described. The effect of this double-counting would be to bias the summary statistics towards the LoS from these settings. Although this is acknowledged as an issue, this was not considered as an exclusion criteria as it would have resulted in the exclusion of many studies. The overall benefit of inclusion was deemed to out-weigh the potential biases which may arise as a result of overlapping patient populations.

In this review we were only able to distinguish between "general hospital LoS" and "ICU LoS", with many studies only reporting an overall LoS. This overall LoS will include both general hospital and ICU admissions within it. There is a need for more granularity with respect to patient pathways, distinguishing between admissions to different levels of care within one hospital episode in order to better inform healthcare contingencies. Patients may, for example, be transferred to ICU on more than one occasion during their stay, which is important to factor in when ICU capacity is particularly limited.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2020. . https://doi.org/10.1101/2020.04. 30.20084780 doi: medRxiv preprint Changes in hospital demand may have also affected our estimates. At the beginning of the outbreak and in certain settings, hospitals were being used to isolate patients who were unable to isolate effectively at home [11, 12] . This means that LoS for patients in some of the earlier studies within this dataset could have been longer due this logistical reason, rather than clinical need. Studies which mentioned this explicitly were excluded, yet there may still be others which were not so transparent. In addition, it is possible that, as hospitals reach the limits of their capacity, a more stringent triage policy may be implemented and the most critical patients may not be transferred to ICU. Despite this, we did not observe a trend when looking at the reported LoS estimates over time, suggesting that this is not in fact an important issue in our data.

Finally, many studies had incomplete follow-up with respect to LoS and, as a result, patients still hospitalised at the end of the study were not included in the summary statistics (right-truncation). This will bias estimates towards shorter LoS, as patients with longer LoS will not be included. A study by Lapidus et al. [53] investigated the bias associated with estimating average ICU LoS for COVID-19 patients based on observed LoS of discharged patients before follow-up of the entire patient cohort was completed. As expected, the authors found that the average LoS estimated at three months of follow-up was much longer than that estimated at one month. This potentially affects our estimates, given that 37 (out of 52) studies had incomplete follow-up with regards to LoS; although on comparison the difference between the groups was slight, and estimates where follow-up was complete were overall shorter. Several studies included still-hospitalised patients in their LoS summary without accounting for censoring [33, 34, [36] [37] [38] [39] [40] [41] , which potentially alters interpretation of the values.

We found that LoS is often not the primary measure of interest in studies which report it, however it is an important parameter when it comes to forecasting bed occupancy during an outbreak. By conducting this review we have systematically gathered a range of published estimates, providing a source from which researchers and decision makers can obtain estimates specific to their population of interest (e.g. with respect to comorbidities) and allowing comparison of LoS between several different populations and settings.

There have been numerous previous studies which have aimed to forecast the number of hospital beds required for COVID-19 patients [16] [17] [18] [19] [20] [21] [22] 54] . Many of these studies published so far have used point estimates, only originating from one study which often does not reflect the context of interest. In particular, many used estimates from Zhou et al. [55] which reported a shorter general hospital LoS (median 11·0, IQR 7·0-14·0; Fig. 2) , and a comparable ICU LoS (median 8·0, IQR 4·0-12·0; Fig. 3 ), compared with other studies from China. However, both of these were still longer than LoS estimates reported by studies outside of China. This means that the bed-forecasting studies relying on LoS estimates from Zhou et al. may be overestimating the number of beds required. The LoS estimate is a critical parameter within a bed forecasting model, and as such any model is likely to be very sensitive to the value or distribution being assumed, with huge implications for policy and planning.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2020. . https://doi.org/10.1101/2020.04. 30.20084780 doi: medRxiv preprint This review has highlighted several potential sources of variation in LoS, and identified common issues and biases which influence each individual estimate. This gives a motivation for considering a wider range of values than can be obtained in a single study, aiming instead to capture the overall distribution of LoS across a variety of possible patient trajectories. Here we have included estimates of the overall LoS distribution in two settings (China/Other) for which we obtained sufficient data.

It is preferable to use data from the setting for which you are trying to forecast bed occupancy (as was done by the IHME COVID-19 health service utilization forecasting team [15] ), however data on completed patient stays will often not be available until well after the onset of the epidemic. Furthermore, LMICs may have reduced capacity for surveillance and monitoring in order to obtain these data. In such cases, where countries are in the early stages of an outbreak, it would be better to use a conservative (i.e broad) distribution of LoS from another setting. As the pandemic progresses and more countries observe patients completing their hospital episodes, it will be possible to add further setting-specific summaries and improve this distribution.

As far as the authors are aware, the approach demonstrated here to summarise median and IQRs across multiple studies has not been proposed before, although there are similarities with the approach taken by others in the CMMID Working Group to pool R 0 estimates [56] . We present an intuitive method which exploits two optimisation methods to fit parametric distributions based on reported summary statistics rather than individual data, then samples across them. In this way we capture the central tendency and overall variation between a set of quantiles from different study populations. This allows multiple sources of evidence to be consolidated into a single distribution which can be used in bed forecasting going forward. By providing both the code for this analysis and our summary distributions, better bed occupancy predictions can be made in the future.

This review summarised the available literature to provide estimates of LoS for general admission and ICU which can be applied for planning and preparedness for SARS-CoV-2. We found substantial differences between China and other settings in terms of total hospital stay, but little evidence for an impact on LoS of time of study, age or disease severity. We present summary distributions which can be used within models making predictions about bed requirements, and suggest that this may be a more robust and realistic way to characterise LoS than relying on summary data from just one setting or hospital. The majority of the data presented in this review comes from China and, as more data become available, it will be important to update this with setting-specific LoS estimates. Understanding the duration of hospitalisation of COVID-19 patients is critical for providing insights as to when hospitals will reach capacity, as well predicting associated staff or equipment requirements.

The authors declare that they have no competing interests.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2020. . https://doi.org/10.1101/2020.04.30.20084780 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2020. . https://doi.org/10.1101/2020.04.30.20084780 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2020. . https://doi.org/10.1101/2020.04.30.20084780 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2020. . https://doi.org/10.1101/2020.04.30.20084780 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2020. Table 1 . Tables . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2020. . https://doi.org/10.1101/2020.04. 30.20084780 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2020. The study dates are based on discharge dates and not admission dates. Before Jan 11, 2020, SARS-CoV-2 RNA detection results were not available in the electronic medical records, from which data for this study were obtained retrospectively; therefore, this study includes 29 of the 41 patients originally reported on.

* median (IQR); **mean ± SD; ***range . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 5, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 5, 2020. Length of stay in hospital, by study−specified disease severity Studies ordered by study_date. Weighted mean at 11.3 days.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2020. 

Coronavirus disease (COVID-2019) situation report

Critical care crisis and some recommendations during the COVID-19 epidemic in China

China Critical Care Clinical Trials Group (CCCCTG): Intensive care during the coronavirus epidemic

COVID-19 and Italy: what next?

On the front lines of coronavirus: the Italian response to covid-19

The resilience of the Spanish health system against the COVID-19 pandemic. The Lancet Public Health 0

Facing Covid-19 in Italy -Ethics, Logistics, and Therapeutics on the Epidemic's Front Line

Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis

Features, Evaluation and Treatment Coronavirus (COVID-19). In: StatPearls. StatPearls Publishing

Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19)

Fangcang shelter hospitals: a novel concept for responding to public health emergencies

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A systematic review and meta-analysis

How many are at increased risk of severe COVID-19 disease? Rapid global, regional and national estimates for 2020. medRxiv

Forecasting COVID-19 impact on hospital bed-days, ICU-days, ventilator-days and deaths by US state in the next 4 months. preprint, Infectious Diseases (except HIV/AIDS

Forecasting ultra-early intensive care strain from COVID-19 in England. medRxiv

A model to forecast regional demand for COVID-19 related hospital beds. medRxiv

Locally Informed Simulation to Predict Hospital Capacity Needs During the COVID-19 Pandemic

COVID-19: Forecasting short term hospital needs in France. medRxiv

Projecting hospital utilization during the COVID-19 outbreaks in the United States

Projecting demand for critical care beds during COVID-19 outbreaks in Canada

Demand for hospitalization services for COVID-19 patients in Brazil. medRxiv

Fitting the distributions of length of stay by parametric models

mixdist: Finite Mixture Distribution Models

distcrete: Discrete Distribution Approximations

R: stats package | R Documentation

latf orm C OV ID − 19 R eport8AP R20.pdf 28. Centre, I.C.N.A.R.: ICNARC report on COVID-19 in critical care

Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. The Lancet Infectious Diseases 0

A quickly, effectively screening process of novel corona virus disease 2019 (COVID-19) in children in Shanghai

Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults

for the COVID-19 Lombardy ICU Network: Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region

Covid-19 in Critically Ill Patients in the Seattle Region -Case Series

Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease

Clinical Characteristics of Coronavirus Disease 2019 in China

Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression

Survival analysis of hospital length of stay of novel coronavirus (COVID-19) pneumonia patients in Sichuan

Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Pregnancy In China: A Retrospective Cohort Study. medRxiv

COVID-19 infection induces readily detectable morphological and inflammation-related phenotypic changes in peripheral blood monocytes, the severity of which correlate with patient outcome. medRxiv

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in

Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study

The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: a retrospective clinical study. medRxiv

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

CDC: Coronavirus Disease

Discharge criteria for confirmed COVID-19 cases

The Impact of Hospital and ICU Organizational Factors on Outcome in Critically Ill Patients: Results From the Extended Prevalence of Infection in Intensive Care Study*

Incidence, clinical outcomes, and transmission dynamics of hospitalized 2019 coronavirus disease among 9,596,321 individuals residing in California and Washington, United States: a prospective cohort study

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Heart injury signs are associated with higher and earlier mortality in coronavirus disease 2019 (COVID-19). medRxiv

Biased and unbiased estimation of the average lengths of stay in intensive care units in the COVID-19 pandemic. medRxiv

Forecasting COVID-19 impact on hospital bed-days, ICU-days, ventilator-days and deaths by US state in the next 4 months. medRxiv

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

The effect of non-pharmaceutical interventions on COVID-19 cases, deaths and demand for hospital services in the UK: a modelling study. medRxiv

COVID-19 in a designated infectious diseases hospital outside Hubei Province

A Trial of Lopinavir

Clinical Features and Short-term Outcomes of 102 Patients with Corona Virus Disease

Clinical progression of patients with COVID-19 in Shanghai

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Epidemiological and clinical features of 291 cases with coronavirus disease 2019 in areas adjacent to Hubei

Kidney impairment is associated with in-hospital death of COVID-19 patients. medRxiv

Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study

The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan

Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan: A Retrospective Observational Study

Clinical Features of COVID-19-Related Liver Damage

Epidemiological, Clinical Characteristics and Outcome of Medical Staff Infected with COVID-19 in Wuhan, China: A Retrospective Case Series Analysis. medRxiv

Clinical characteristics of 51 patients discharged from hospital with COVID-19 in ChongqingChina. medRxiv

Clinical characteristics of refractory COVID-19 pneumonia in

Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel Coronavirus

Epidemiological and clinical features of 2019-nCoV acute respiratory disease cases in Chongqing municipality

Comparison of Hospitalized Patients With ARDS Caused by COVID-19 and H1N1

Clinical characteristics and reasons of different duration from onset to release from quarantine for patients with COVID-19 Outside Hubei province

Longitudinal analysis of laboratory findings during the process of recovery for patients with COVID-19. medRxiv

Clinical Characteristics of Imported Cases of Coronavirus Disease 2019 (COVID-19) in Jiangsu Province: A Multicenter Descriptive Study

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv

Acute kidney injury in patients hospitalized with COVID-19 in Wuhan, China: A single-center retrospective observational study. medRxiv

Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: A retrospective study

Acute kidney injury at early stage as a negative prognostic indicator of patients with COVID-19: a hospital-based retrospective analysis. medRxiv

Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in patients with SARS-CoV-2 infection. medRxiv

The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients

The authors gratefully acknowledge funding of the SPEAK India Consortium